Quantitative prediction of metabolic inhibition of midazolam by erythromycin, diltiazem, and verapamil in rats: Implication of concentrative uptake of inhibitors into liver

Journal of Pharmacology and Experimental Therapeutics

Volumn 292, Issue 3, 2000, Pages 1118-1126

  Yamano, Katsuhiro ^a,c   Yamamoto, Koujirou ^d   Kotaki, Hajime ^b   Takedomi, Sayuri ^e   Matsuo, Hirotami ^e   Sawada, Yasufumi ^e   Iga, Tatsuji ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c ASTELLAS PHARMA INC   (Japan)

^d GUNMA UNIVERSITY   (Japan)

^e KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; DILTIAZEM; ERYTHROMYCIN; MIDAZOLAM; STEROID 11BETA MONOOXYGENASE; TACROLIMUS; VERAPAMIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALCULATION; DRUG DISPOSITION; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RAT; STEADY STATE;

ANIMALS; BLOOD PROTEINS; DILTIAZEM; DRUG INTERACTIONS; ERYTHROMYCIN; HYPNOTICS AND SEDATIVES; LIVER; MALE; MIDAZOLAM; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; VERAPAMIL;

EID: 0034059924     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Ahonen J, Olkkola KT and Neuvonen PJ (1995) Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br J Clin Pharmacol 40:270-272.
2. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD and Chenery RJ (1995) Ketoconazole and sulphaphenazole as the respective selective inhibitors of P450 3A and 2C9. Xenobiotica 26:261-270.
3. Backman JT, Aranko K, Himberg JJ and Olkkola KT (1994) A pharmacokinetic interaction between roxithromycin and midazolam. Eur J Clin Pharmacol 46:551-555.
4. Delaforge M, Jaouen M and Mansuy D (1984) The cytochrome P-450 metabolite complex derived from troleandomycin: Properties in vitro and stability in vivo. Chem-Biol Interact 51:371-376.
5. Delaforge M, Sartori E and Mansuy D (1988) In vivo and in vitro effects of a new macrolide antibiotic roxithromycin on rat liver cytochrome P-450: Comparison with troleandomycin and erythromycin. Chem-Biol Interact 68:179-188.
6. Fee JPH, Collier PS, Howard PJ and Dundee JW (1987) Cimetidine and ranitidine increase midazolam bioavailability. Clin Pharmacol Ther 41:80-84.
7. Floren LC, Bekersky I, Benet JLZ, Mekki Q, Dressler D, Lee JW, Roberts JP and Hebert MF (1997) Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 62:41-49.
8. Franklin MR (1991) Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds. Methods Enzymol 206:559-573.
9. Ghosal A, Satoh H, Thomas PE, Bush E and Moore D (1996) Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metab Dispos 24:940-947.
10. Gomez DY, Wacher SJ, Tomlanovich, Hebert MF and Benet LZ (1995) The effect of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 58:15-19.
11. Gray MR, Saville BA and Tam YK (1987) Mechanisms of lidocaine kinetics in the isolated perfused rat liver: Evaluation of liver models for time-dependent behavior. Drug Metab Dispos 15:22-26.
12. Hoffman DJ, Seifert T, Borre A and Nellans HN (1995) Method to estimate the rate and extent of intestinal absorption in conscious rats using an absorption probe and portal blood sampling. Pharm Res 12:889-894.
13. Hung J, Hackett PL, Gordon SPF and Ilett KF (1988) Pharmacokinetics of diltiazem in patients with unstable angina pectoris. Clin Pharmacol Ther 43:466-470.
14. Ito K, Iwatsubo T, Kanamitsu S, Ueda H, Suzuki H and Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver. Pharmacol Rev 50:387-411.
15. Kremers P, Beaune P, Cresteil T, De Graeve J, Columelli S, Leroux JP and Gielen JE (1981) Cytochrome P-450 monooxygenases activities in human and liver microsomes. Eur J Biochem 118:599-606.
16. Lindstrom TD, Hanssen BR and Wrighton SA (1993) Cytochrome P-450 complex formation by dirithromycin and other macrolides in rat and human livers. Antimicrob Agents Chemother 37:265-269.
17. Lown KS, Mayo RR, Leichtman AB, Hsiao H, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ and Watkins PB (1997) Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 62:248-260.
18. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
19. Masubuchi Y, Araki J, Narimatsu S and Suzuki T (1992) Metabolic activation of lidocaine and covalent binding to rat liver microsomal protein. Biochem Pharmacol 43:2551-2557.
20. Meijer DKF, Mol WEM, Muller M and Kurz G (1990) Carrier-mediated transport in the hepatic distribution and elimination of drugs, with special reference to the category of organic cations. J Pharmacokinet Biopharm 18:35-70.
21. Murray M and Butler AM (1996) Enhanced inhibition of microsomal cytochrome P450 3A2 in rat liver during diltiazem biotransformation. J Pharmacol Exp Ther 279:1447-1452.
22. Nelson WL and Olsen LD (1988) Regiochemistry and enantioselectivity in the oxidative N-dealkylation of verapamil. Drug Metab Dispos 16:834-841.
23. Olkkola KT, Ahonen J and Neuvonen PJ (1996) The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 82:511-516.
24. Olkkola KT, Aranko K, Luurila H, Killer A, Saarnivaara L, Himberg JJ and Neuvonen PJ (1993) A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 53:298-305.
25. Olkkola KT, Backman JT and Neuvonen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55:481-485.
26. Omura T and Sato R (1964) The monoxide carbon binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
27. Pessayre D, Tinel M, Larrey D, Cobert B, Funck-Brentano C and Babany G (1983) Inactivation of cytochrome P-450 by a troleandomycin metabolite: Protective role of glutathione. J Pharmacol Exp Ther 224:685-691.
28. Saville BA, Gray MR and Tam YK (1989) Evidence for lidocaine-induced enzyme inactivation. J Pharm Sci 78:1003-1008.
29. Sawada Y, Takanaga H and Iga T (1996) Desirable state of drug interaction section in package insert circulars. J Pract Pharm (in Japanese) 47:1535-1565.
30. Schwartz JB, Abernethy DR, Taylor AA and Mitchell JR (1985) An investigation of the cause of accumulation of verapamil during regular dosing in patients. Br J Clin Pharmacol 19:512-516.
31. Tabata K, Yamaoka K, Fukuyama T and Nakagawa T (1995) Evaluation of intestinal absorption into the portal system in enterohepatic circulation by measuring the difference in portal-venous blood concentrations of diclofenac. Pharm Res 12:880-888.
32. Takedomi S, Matsuo H, Yamano K, Yamamoto K, Iga T and Sawada Y (1998) Quantitative prediction of the interaction of midazolam and histamine H2 receptor antagonists in rats. Drug Metab Dispos 26:318-323.
33. Tinel M, Descatoire V, Larrey D, Loeper J, Labbe G, Letteron P and Pessayre D (1989) Effects of clarithromycin on cytochrome P-450: Comparison with other macrolides. J Pharmacol Exp Ther 250:746-751.
34. Yamano K, Yamamoto K, Kotaki H, Sawada Y and Iga T (1999) Quantitative prediction of metabolic inhibition of midazolam by azole antifungal agents in rats: Implication of concentrative uptake of inhibitors into liver. Drug Metab Dispos 27:395-402.
35. Yamaoka K, Tanigawara Y, Nakagawa T and Uno T (1981) A pharmacokinetics analysis program (MULTI) for microcomputer. J Pharmacobiodyn 4:879-885.
36. Yamazaki H, Urano T, Hiroki S and Shimada T (1996) Effects of erythromycin and roxithromycin on oxidation of testosterone and nifedipine catalyzed by CYP3A4 in human liver microsomes. J Toxicol Sci 21:215-226.
37. Yamazaki M, Suzuki H and Sugiyama Y (1996) Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm Res 13:497-513.
38. Yeung PKF, Mosher SJ, Quilliam MA and Montague TJ (1990) Species comparison of pharmacokinetics and metabolism of diltiazem in human, dogs, rabbits, and rats. Drug Metab Dispos 18:1055-1059.